Genetic Technologies (ASX:GTG) EBIT per Share: A$0.00 (TTM As of Jun. 2024)


What is Genetic Technologies EBIT per Share?

Genetic Technologies ASX:GTG EBIT per Share is A$0.00 as of Jun. 2024.

Genetic Technologies's EBIT per Share for the three months ended in Jun. 2024 was A$0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was A$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Genetic Technologies's EBIT per Share or its related term are showing as below:

ASX:GTG's 3-Year EBIT Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 13
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Genetic Technologies's EBIT for the three months ended in Jun. 2024 was A$0.00 Mil.

Genetic Technologies  (ASX:GTG) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Genetic Technologies EBIT per Share Related Terms

Genetic Technologies EBIT per Share Historical Data

* Premium members only.

The historical data trend for Genetic Technologies's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Technologies EBIT per Share Chart

Genetic Technologies Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 -0.08 -0.08 -0.12 -0.09

Genetic Technologies Quarterly Data
Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genetic Technologies EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Genetic Technologies's EBIT per Share for the fiscal year that ended in Jun. 2024 is calculated as

EBIT per Share(A: Jun. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-11.966/132.217
=-0.09

Genetic Technologies's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

EBIT per Share(Q: Jun. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=0/132.217
=0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of A$0.00 mean?
Genetic Technologies (ASX:GTG) has a EBIT per Share of A$0.00 as of Jun. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genetic Technologies and its competitors.
Is Genetic Technologies' EBIT per Share too high?
Genetic Technologies' current EBIT per Share is A$0.00.
How does Genetic Technologies' EBIT per Share compare to LDDD and NOTV?
Genetic Technologies' EBIT per Share of A$0.00 can be compared against companies in the Medical Diagnostics & Research industry. The industry median EBIT per Share is 13.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 13.00, based on 169 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Genetic Technologies and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Technologies's current EBIT per Share is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Technologies stock overvalued right now?
Genetic Technologies (ASX:GTG) has a current EBIT per Share of A$0.00. The current EBIT per Share is A$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Genetic Technologies (ASX:GTG), the current EBIT per Share is A$0.00 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Technologies Business Description

Address 60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.